WO1993005650A1 - Methods and compositions with aldehyde stabilizing solution - Google Patents

Methods and compositions with aldehyde stabilizing solution Download PDF

Info

Publication number
WO1993005650A1
WO1993005650A1 PCT/US1992/007925 US9207925W WO9305650A1 WO 1993005650 A1 WO1993005650 A1 WO 1993005650A1 US 9207925 W US9207925 W US 9207925W WO 9305650 A1 WO9305650 A1 WO 9305650A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
tissue
glyoxal
amount
pathology
Prior art date
Application number
PCT/US1992/007925
Other languages
French (fr)
Inventor
Gerald W. Camiener
Original Assignee
Camiener Gerald W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camiener Gerald W filed Critical Camiener Gerald W
Priority to CA002119554A priority Critical patent/CA2119554C/en
Priority to JP5506263A priority patent/JPH07507266A/en
Priority to EP92920955A priority patent/EP0627879A1/en
Priority to AU26835/92A priority patent/AU669673B2/en
Publication of WO1993005650A1 publication Critical patent/WO1993005650A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N3/00Preservation of plants or parts thereof, e.g. inhibiting evaporation, improvement of the appearance of leaves or protection against physical influences such as UV radiation using chemical compositions; Grafting wax

Definitions

  • Example 1 discloses a mixture of 37 % water, 30 % glyoxal at 40 % strength and 20 % methanol, with a use as an embalming fluid.
  • Myron Yanoff et al. "Glutaraldehyde Fixation of Whole Eyes", American J. Clinical Pathology, Vol. 44, pp. 167-171 (1965), discloses the glutaraldehyde fixation of whole eyes. Rendon, U.S. Patent 3,057,775, in Examples 1 and 3 discloses an aqueous mixture of an alkanol, glutaraldehyde, sodium acetate as well as phenol, glycerin, and a wetting agent for use as an embalming fluid.
  • a method of providing pathology-stable tissue which comprises treating said tissue with an aqueous solution (I) of glyoxal in an amount sufficient to prevent major degenerative changes in said tissue, whereby said tissue remains in a state suitable for micro-, or macroscopic examination sufficient for pathological or experimental examination and diagnosis.
  • aqueous solution (I) of glyoxal in an amount sufficient to prevent major degenerative changes in said tissue, whereby said tissue remains in a state suitable for micro-, or macroscopic examination sufficient for pathological or experimental examination and diagnosis.
  • the glyoxal is used alone or in admixture with other components.
  • the glyoxal is used in combination with a balanced mixture of other components. In the absence of such a proper mixture, good microscopic appearances are not obtained.
  • the glyoxal is an aldehyde addition product in the form of a bisulfite, hydrate or alcohol addition product.
  • the addition product may be used as a liquid form, or in the solid form to which water and/or an alkanol can be added to provide a liquid mixture, or in combination with other materials.
  • the bisulfite When used, it is preferably in the form of an metal salt, preferably the sodium or potassium salt.
  • the addition product used is preferably a glycol such as ethylene glycol, the product of which is known as dioxanediol.
  • a solid form of glyoxal is particularly advantageous for kits in that leakage, shipping, and stability problems are eliminated. Water and/or an alkanol is added by the user shortly before a sample is added to the kit.
  • Tissues suitable for glyoxal treatment include tissues of animal, or plant origin, but particularly those of mammalian and human origin.
  • glyoxal is present in an amount of from about 0.08 % to about 36 % of the overall solution. More preferably, glyoxal is present in an amount of from about 0.1 % to about 20 % percent of the overall solution. Also included within the solution may be from about 0.15 % to about 36 % of a C ⁇ _ 4 alkane-mono- di- or triol.
  • Alkanols include monools like ethanol, diols like ethylene glycol and triols like glycerol. Glycerol is particularly suited for a stabilizing solution (I) that has as one of its objectives the maintenance of a tissue sample in a more pliable condition.
  • Mono- and diol-alkanes are particularly useful in permitting faster tissue penetration of the stabilizing solution which is very important for preserving of larger tissue samples and organs. Mono- and diol-alkanes also are particularly effective in stabilizing dialdehydes in solution, thereby providing active reactants for longer times.
  • the stabilizing .solution is prepared by mixing an appropriate amount of glyoxal bisulfite addition product in water, together with sodium or potassium phosphates, to give a pH of 6.5.
  • the resulting pH buffered stabilizing solution maintains physiologic conditions while it is stabilizing the tissue, is preventing autolysis, and is maintaining the tissue in a condition suitable for pathology observation.
  • said solution includes at least one C ⁇ _ 4 alkane mono-, di- or triol at a concentration of from about 0.4 % to about 32 % of said solution, whereby the penetration of said solution into said tissue is facilitated.
  • said solution includes an ionic or nonionic chemical in an amount of from about 0.1 % to about 14 % of said solution, whereby the osmotic pressure effects of said solution is altered, thereby modifying and/or stabilizing said tissue for subsequent examination.
  • sea lamprey eels are stabilized using a glyoxal solution containing 3 % sodium chloride.
  • additional and specific micro-anatomical stabilization effects are obtained by the inclusion of various specific reactants including mercuric salts, trichloroacetic acid, acetic acid, picric acid and potassium dichromate, in amounts of from abut 0.07 % to about 40.0 %.
  • said glyoxal solution contains 37 % picric acid, and 5 % glacial acetic acid.
  • said glyoxal solution contains 4.5 % mercuric chloride, 0.5 % sodium chloride and 2 % trichloracetic acid.
  • Other reactants can include chromium trioxide, copper salts, and various other heavy-metal and transition-metal salts.
  • a method for simultaneously providing a pathology-stable tissue while decalcifying calcified regions within said tissue wherein said solution includes an acid and or acid-salt such as formic, hydrochloric, citric and nitric acids and/or their alkali-metal or ammonium salt forms in amount of from about 0.3 % to about 75 %.
  • an acid and or acid-salt such as formic, hydrochloric, citric and nitric acids and/or their alkali-metal or ammonium salt forms in amount of from about 0.3 % to about 75 %.
  • the solution may additionally, or alternatively, include a chelating agent, in an amount from about 0.1 % to about 18 %, such as ethylene-diamine-tetra-acetic acid, or an alkali-metal-salt or ammonium-salt thereof.
  • a chelating agent such as ethylene-diamine-tetra-acetic acid, or an alkali-metal-salt or ammonium-salt thereof.
  • a tissue sample has been stabilized in a state suitable for pathology and/or experimental examination, and/or diagnosis.
  • the microscopic and macroscopic cell, tissue and organ constituents will have been maintained in as lifelike a condition as possible, substantially free from the autolytic and other changes that occur when normal tissue is removed from a living being or organism (as in the case of a biopsy sample) , or when the entire body or organism dies and a portion of the body is to be preserved for subsequent examination.
  • tissue refers to any form of tissue, whether a thin slice taken, for example, from a possibly cancerous tissue for purpose of a biopsy, or any larger portion that includes such tissue, for example, a liver or a kidney.
  • the application of the solution (I) serves to stabilize the tissue in as normal as possible a state, and immediately stops metabolic reactions, autolytic changes and microbial degradative changes.
  • Autolysis is a process whereby the normal cellular enzymes and components degrade and destroy the cell structure itself.
  • kits for maintaining a pathology-stable preparation which comprises a female receptacle means and a male closure means, and contained within said female receptacle means an aqueous solution containing a glyoxal addition product in an amount sufficient to prevent major degenerative changes in the sample reserved for pathological examination.
  • a kit also can contain a solid form of a glyoxal addition product to which water and/or alkanol is added prior to the sample being introduced.
  • the stabilizing solution also can contain various other pH buffering and osmotic-pressure affecting chemicals, as well as various special-effect reactants as described earlier.
  • the kit is for maintaining a stool sample in a stabilized form so that parasites, worms and/or protozoans contained in the stool sample are maintained in a condition suitable for analysis and evaluation at a later time by an appropriate laboratory.
  • Said kit includes a female receptacle means and a male closure means and a stabilizing solution containing glyoxal addition product.
  • said tissue is in the form of an organ or an entire organism which is .to be preserved for a prolonged period of time, whereby said solution prevents substantial degenerative changes within this period.
  • kits for the collection, stabilization, and maintenance of other bodily fluids, solids, exudates and/or secretions such as phlegm, mucous, semen, pus and urine.
  • a composition capable of providing pathology-stable tissue when a tissue is immersed in said composition, said composition being an aqueous solution of a glyoxal addition product in an amount sufficient to prevent major degenerative changes in said tissue, glyoxal being present in an amount of from about 0.08 % to about 36 % percent of the overall solution, and said solution including from about 0.15 % to about 36 % of a C 2 _ 4 alkane- mono-, di-, or triol to stabilize said solution.
  • a further embodiment provides a solution that includes at least one C 2 _ 4 mono-, di-, or triol alkane at a concentration of from about 0.4 % to about 32 % of said solution, whereby the penetration of said solution into said tissue is facilitated.
  • said solution includes an ionic or nonionic chemical in an amount of from about 0.1 % to about 14 % of said solution, whereby the osmotic pressure effects of said solution is altered, thereby stabilizing said tissue for subsequent examination.
  • the preferably said solution contains an acid and/or an acid-salt and/or a chelating agent to effect decalcification of calcified portions of tissues.
  • this first aspect of the invention there is provided a small sample of tissue from either a biopsy or a fresh cadaver that is treated with the solution (I) in an amount sufficient to prevent autolysis of the tissue by native enzymes that upon cessation of living state of the tissue operate to digest and to disintegrate the tissue, and to prevent other degenerative changes in the tissue.
  • a test-stable stool sample kit comprising means for maintaining a stool sample in a condition for evaluation at a later time by an appropriate laboratory including a female receptacle means and a male closure means and the stabilizing solution (I) .
  • a typical female receptacle means may be mentioned wide mouth jar containers of plastic or glass or the like with a screw pattern to accommodates a male screw cap closure.
  • Another female receptacle means could be a bag or pouch, and the "male" closure could be a tie or clamp.
  • the female receptacle means may be of any shape, size or form provided it is such as to accommodate a sample of tissue, organ or bodily product that is to be inserted into the female receptacle means.
  • the stabilizing solution (I) reacts quickly with a variety of groups in the cell to stop enzyme actions, to fix structural features, to stop microbial actions and generally to maintain the sample in a manner as close to the form and appearance of the living tissue as possible, whereby the pathology examination is facilitated. While formaldehyde and other usually-used fixatives, when used alone, will provide acceptable microscopic appearing preparations, glyoxal used alone will not. The additional combination of components is required to provide good microscopic appearances.
  • the stabilizing solution (I) is used to prepare parts or whole animals or plants in an anatomically preserved state for a prolonged period of time, and compositions useful in that method.
  • the stabilizing solution (I) of the invention may be used to preserve frogs or other small animals for school laboratory dissection, or entire cadavers or individual organs for medical school instructional and other uses.
  • the stabilizing solution (I) also facilitates the preservation of the specimen by killing and/or inhibiting any microorganisms that otherwise might be present or develop and thereby degrade the specimen.
  • stabilization of a tissue sample was desired for a period of days
  • stabilization for a prolonged period preferably measured in years is the object. It is intended to be used with specimens such as frogs, fetal pigs, cadavers, cats, worms, insects or large organs that are to be used for study or dissection whether in a high school, college medical school, or autopsy setting, or other preservation uses.
  • tissue may be of animal or plant origin. While human tissue, organs, or the entire organism are contemplated, it should be noted that the invention is contemplated
  • At least one additional chemical such as mercuric salts, trichloroacetic acid, acetic acid, picric acid, potassium dichromate, phenol, biphenol, phenols, cresols, quaternary ammonium compounds, surfactants, antibiotics copper salts, sulfosalicylic acid, osmic acid, platinum salts, cadmium salts, cobalt salts and uranyl salts.
  • the amount of any of these additional chemicals would be from about 0.07 % to about 16.5 %.
  • Kidneys are cut in half so.that one- end serves as a control for the other end. Kidney halves are immersed in at least 10 times their volume of the said prepared solution and allowed to stand for varying periods of time. They then are prepared for pathological and histological examination. After 6 hours of exposure to the solution, the center-most portions of the kidney show good penetration of the solution whilst the controls that were immersed in the same solution without ethyl alcohol show very much poorer penetration in the center-most portions.
  • Kidneys prepared and treated in accordance with Example 2 are examined after 7 and 21 days of immersion in said solution.
  • the kidneys remain in good stabilized condition suitable for pathologic and histologic examination. Good cellular detail is observed, without observable degradative changes.
  • a glass container there is added, in order with mixing, 700 ml of deionized water, 200 ml of ethylene glycol and 100 ml of a 40 % glyoxal solution.
  • the solution is adjusted to pH 6.5 by the drop- wise addition of sodium hydroxide solution under conditions of continuous mixing.
  • the solution is stored for a few days and then is used to stabilize pieces of human tissue prior to histologic processing and examination. Tissues processed with said solution show good preservation and cellular detail. Control tissues treated with the same solution absent the ethylene glycol show poorer preservation. Independent chemical analysis shows that the ethylene-glycol-containing solution has a higher glyoxal concentration than the solution absent the ethylene glycol.
  • a glass container there is added, in order with mixing, 500 ml of deionized water, 200 ml of denatured ethyl alcohol, 150 ml of glycerol, 60 ml of a 40 % glyoxal solution, and 50 ml of a 40 % solution of glyoxal.
  • Intact rat livers are separated into individual lobes and the lobes are used as controls for different experimental conditions. In this example, lobes were immersed for 14 days in 10-fold excesses of said solution. The lobes are then processed and examined.
  • Lobes treated with said solution show good preservation and good tissue consistency with no - evidence of "crumbliness.” Control lobes immersed in the same solution absent the glycerol did not show the same tissue "pliability" and "softness.” Microscopic examination of the test lobes treated with the solution in this example showed good cellular and microcellular detail. Control lobes treated with same solution except that the combination of dialdehydes was not used also show good cellular detail, but the uptake of stain was not as uniform in some sub- cellular details as was seen when the combination of dialdehydes was used.
  • a glass container there is added, in order with mixing, 850 ml of denatured ethyl alcohol, 50 ml of glacial acetic acid and 100 ml of a 40 % glyoxal solution.
  • Various arachnids, insects and plant parts were immersed in said solution and were examined after one week, three weeks and nine months of immersion. All tissues, cells and organisms showed good preservation and good cellular detail.
  • EXAMPLE 8 To a glass container, there is added, in order with mixing, 850 ml of deionized water, 10 g of formic acid, 100 g of trisodium citrate, and 100 ml of a 40 % glyoxal solution. Pieces of mammalian bone are immersed in at least a 10-fold excess of said solution and left for 5-7 days. Subsequent processing and examination show good preservation and good cellular detail. Calcified areas are completely decalcified and shrinkage is not observed.
  • Example 8 The formic acid and sodium citrate in Example 8 were replaced with 100 g of disodium ethylene-diamine tetraacetate. Mammalian teeth were immersed in said modified solution and left for 7-10 days. Subsequent processing and examination showed good preservation and good structure Decalcification appears to complete.
  • a test-stable stool sample kit which includes means for maintaining a stool sample in a condition suitable for analysis at a later time by an appropriate laboratory include a female receptacle means and a male closure means and 30 ml. of an aqueous solution which contains 40 % glyoxal.
  • a typical female receptacle means may be mentioned a 2 oz. wide mouth plastic container with a screw pattern to accommodates a male screw cap closure.
  • the female receptacle means may be of any shape, size or form provided it is such to accommodate a small scraping of bowel sample that is to be inserted into the female receptacle means.
  • Parasites which may be in the stool sample and which may be an object of laboratory examination are preserved in the stool samples to permit the stool sample to be properly used to identify the presence of such parasites.
  • EXAMPLE 11 In the test-stable stool sample kit of Example 10, the mentioned aqueous solution is replaced by 800 mg of dioxanediol (solid) , which is dissolved in 20 ml of an aqueous solution prior to inserting the stool sample. Parasites which may be in the stool sample and which may be an object of laboratory examination are preserved in the stool samples to permit the stool sample to be properly used to identify the presence of such parasites.
  • a freshly excised primate heart is perfused with a solution of glyoxal as prepared in Example 4 except that the pH was not adjusted. Following perfusion, the heart was left immersed in a closed container for 10 months, and then examined macroscopically and microscopically. The heart is preserved in good condition with no apparent degradative changes, and is suitable for student observation.
  • An adult bull frog is extinguished under ether, and is perfused with the solution described in Example 12 to which sodium chloride (0.6 %) and cetyltrimethylammonium bromide (0.15 %) have been added.
  • the frog is kept moistened with same solution (under wetted cotton) in a closed container. The frog remains suitable for student dissection for a period of at least one year.

Abstract

Methods are provided to prepare a variety of tissues in a pathology-stable form keyed to the use of an aqueous solution of glyoxal and/or its addition products, including glyoxal in an amount sufficient to prevent autolysis and other degradative changes in various tissues. The said solution is capable of treating a tissue so as to maintain the tissue in a condition suitable for pathology and/or other experimental observation, and/or diagnosis. The stabilizing solution is also useful to prepare parts or whole animals, parasites, and plants in an anatomically preserved state for a prolonged period of time, and compositions useful in that method.

Description

METHODS AND COMPOSITIONS WITH ALDEHYDE STABILIZING SOLUTION
BACKGROUND OF THE INVENTION
The prior art is replete with formaldehyde treatments for various purposes. Chang et al.,. U.S. 4,654,312, teaches a composition for destroying erythrocytes while maintaining leukocytes that comprises formaldehyde. In a representative composition, Example 1, discloses 1 % formaldehyde, 3 % ethylene glycol and 0.25 % sodium citrate at a pH 7.7 ± 0.5. Chang et al. describe this as a "lysing solution" (col. 5, line 33). It is also stated by Chang et al. in a generic disclosure that in lieu of formaldehyde they contemplate about 0.5 to about 4 percent of any short chain aliphatic aldehyde, but preferably formaldehyde (col. 3, line 65 - col. 4, line 2). It is stated that this aldehyde acts as a fixing agent to stabilize the white cells while the distilled water that is in the mixture acts as a lysing agent to rupture the erythrocytes. While Chang et al. disclose that their composition destroys erythrocytes, Falkowski et al., U.S. Patent 4,136,161, disclose that glyoxal with sodium citrate serves to stabilize erythrocytes. There is no suggestion of the use of an alkanol with the glyoxal. It is also to be noted that contrary to the teachings of Falkowski et al., while monovalent ions such as potassium are indicated in the prior art as useful for stabilization of glutaraldehyde, research that has been conducted subsequently has shown that the aldehyde is destroyed and not saved by the potassium ion treatment. Buchalter, U.S. 3,983,252, discloses at col. 7, Example 1, a 50 % aqueous solution, 40 cc. glutaraldehyde with 7 gm sodium citrate and 50 cc propylene glycol, and 960 cc water. The use of this composition is as a disinfectant, with no suggestion of providing histological stabilization. In a generic recitation of various other ingredients, glyoxal is included as a recitation of one of the aldehydes that might be used. Jones, U.S. Patent 2,333,182, at
Example 1, discloses a mixture of 37 % water, 30 % glyoxal at 40 % strength and 20 % methanol, with a use as an embalming fluid. Myron Yanoff et al., "Glutaraldehyde Fixation of Whole Eyes", American J. Clinical Pathology, Vol. 44, pp. 167-171 (1965), discloses the glutaraldehyde fixation of whole eyes. Rendon, U.S. Patent 3,057,775, in Examples 1 and 3 discloses an aqueous mixture of an alkanol, glutaraldehyde, sodium acetate as well as phenol, glycerin, and a wetting agent for use as an embalming fluid. Specific use of glyoxal is not suggested. Ryan, U.S. Patent 4,198,206, discloses stabilization of platelet with the use of glutaraldehyde, and suggests that ethylene glycol is used as an "antifreeze", i.e., to protect against freezing of the stabilizing solution, col. 1, lines 42-47.
DETAILED DESCRIPTION
In accordance with a first aspect of the invention there is provided a method of providing pathology-stable tissue which comprises treating said tissue with an aqueous solution (I) of glyoxal in an amount sufficient to prevent major degenerative changes in said tissue, whereby said tissue remains in a state suitable for micro-, or macroscopic examination sufficient for pathological or experimental examination and diagnosis.
The glyoxal is used alone or in admixture with other components. The glyoxal is used in combination with a balanced mixture of other components. In the absence of such a proper mixture, good microscopic appearances are not obtained. In one embodiment, the glyoxal is an aldehyde addition product in the form of a bisulfite, hydrate or alcohol addition product. When the glyoxal is an aldehyde addition product in the form of a bisulfite, hydrate, alcohol, or glycol addition product, the addition product may be used as a liquid form, or in the solid form to which water and/or an alkanol can be added to provide a liquid mixture, or in combination with other materials. When the bisulfite is used, it is preferably in the form of an metal salt, preferably the sodium or potassium salt. When in the form of an alcohol addition product, the addition product used is preferably a glycol such as ethylene glycol, the product of which is known as dioxanediol. The use of a solid form of glyoxal is particularly advantageous for kits in that leakage, shipping, and stability problems are eliminated. Water and/or an alkanol is added by the user shortly before a sample is added to the kit.
Tissues suitable for glyoxal treatment include tissues of animal, or plant origin, but particularly those of mammalian and human origin.
In one embodiment, glyoxal is present in an amount of from about 0.08 % to about 36 % of the overall solution. More preferably, glyoxal is present in an amount of from about 0.1 % to about 20 % percent of the overall solution. Also included within the solution may be from about 0.15 % to about 36 % of a Cχ_4 alkane-mono- di- or triol. Alkanols include monools like ethanol, diols like ethylene glycol and triols like glycerol. Glycerol is particularly suited for a stabilizing solution (I) that has as one of its objectives the maintenance of a tissue sample in a more pliable condition. Mono- and diol-alkanes are particularly useful in permitting faster tissue penetration of the stabilizing solution which is very important for preserving of larger tissue samples and organs. Mono- and diol-alkanes also are particularly effective in stabilizing dialdehydes in solution, thereby providing active reactants for longer times.
In another preferred embodiment, the stabilizing .solution is prepared by mixing an appropriate amount of glyoxal bisulfite addition product in water, together with sodium or potassium phosphates, to give a pH of 6.5. The resulting pH buffered stabilizing solution maintains physiologic conditions while it is stabilizing the tissue, is preventing autolysis, and is maintaining the tissue in a condition suitable for pathology observation. In a preferred embodiment, said solution includes at least one Cχ_4 alkane mono-, di- or triol at a concentration of from about 0.4 % to about 32 % of said solution, whereby the penetration of said solution into said tissue is facilitated. In a further embodiment, said solution includes an ionic or nonionic chemical in an amount of from about 0.1 % to about 14 % of said solution, whereby the osmotic pressure effects of said solution is altered, thereby modifying and/or stabilizing said tissue for subsequent examination. In one such embodiment, sea lamprey eels are stabilized using a glyoxal solution containing 3 % sodium chloride.
In other embodiments, additional and specific micro-anatomical stabilization effects are obtained by the inclusion of various specific reactants including mercuric salts, trichloroacetic acid, acetic acid, picric acid and potassium dichromate, in amounts of from abut 0.07 % to about 40.0 %. In one preferred embodiment, said glyoxal solution contains 37 % picric acid, and 5 % glacial acetic acid. Another preferred embodiment, said glyoxal solution contains 4.5 % mercuric chloride, 0.5 % sodium chloride and 2 % trichloracetic acid. Other reactants can include chromium trioxide, copper salts, and various other heavy-metal and transition-metal salts.
In a further aspect of the invention, there is provided a method for simultaneously providing a pathology-stable tissue while decalcifying calcified regions within said tissue wherein said solution includes an acid and or acid-salt such as formic, hydrochloric, citric and nitric acids and/or their alkali-metal or ammonium salt forms in amount of from about 0.3 % to about 75 %. In this embodiment, for the simultaneous preservation of a pathology-stable tissue and decalcification of any calciferous regions within said tissue, the solution may additionally, or alternatively, include a chelating agent, in an amount from about 0.1 % to about 18 %, such as ethylene-diamine-tetra-acetic acid, or an alkali-metal-salt or ammonium-salt thereof.
By a "pathology-stable tissue," there is intended to mean that a tissue sample has been stabilized in a state suitable for pathology and/or experimental examination, and/or diagnosis. In such a stabilized condition, the microscopic and macroscopic cell, tissue and organ constituents will have been maintained in as lifelike a condition as possible, substantially free from the autolytic and other changes that occur when normal tissue is removed from a living being or organism (as in the case of a biopsy sample) , or when the entire body or organism dies and a portion of the body is to be preserved for subsequent examination. As the term is used herein, a "tissue" refers to any form of tissue, whether a thin slice taken, for example, from a possibly cancerous tissue for purpose of a biopsy, or any larger portion that includes such tissue, for example, a liver or a kidney. By applying the solution as soon as possible after removal or death, the application of the solution (I) serves to stabilize the tissue in as normal as possible a state, and immediately stops metabolic reactions, autolytic changes and microbial degradative changes. Autolysis is a process whereby the normal cellular enzymes and components degrade and destroy the cell structure itself.
In a further aspect of the invention there is provided a kit for maintaining a pathology-stable preparation which comprises a female receptacle means and a male closure means, and contained within said female receptacle means an aqueous solution containing a glyoxal addition product in an amount sufficient to prevent major degenerative changes in the sample reserved for pathological examination. Such a kit also can contain a solid form of a glyoxal addition product to which water and/or alkanol is added prior to the sample being introduced. The stabilizing solution also can contain various other pH buffering and osmotic-pressure affecting chemicals, as well as various special-effect reactants as described earlier.
In one embodiment, the kit is for maintaining a stool sample in a stabilized form so that parasites, worms and/or protozoans contained in the stool sample are maintained in a condition suitable for analysis and evaluation at a later time by an appropriate laboratory. Said kit includes a female receptacle means and a male closure means and a stabilizing solution containing glyoxal addition product. In an embodiment, said tissue is in the form of an organ or an entire organism which is .to be preserved for a prolonged period of time, whereby said solution prevents substantial degenerative changes within this period. Other embodiments employ said kit for the collection, stabilization, and maintenance of other bodily fluids, solids, exudates and/or secretions such as phlegm, mucous, semen, pus and urine. In a further aspect of the invention, there is provided a composition capable of providing pathology-stable tissue when a tissue is immersed in said composition, said composition being an aqueous solution of a glyoxal addition product in an amount sufficient to prevent major degenerative changes in said tissue, glyoxal being present in an amount of from about 0.08 % to about 36 % percent of the overall solution, and said solution including from about 0.15 % to about 36 % of a C2_4 alkane- mono-, di-, or triol to stabilize said solution. In this aspect, a further embodiment provides a solution that includes at least one C2_4 mono-, di-, or triol alkane at a concentration of from about 0.4 % to about 32 % of said solution, whereby the penetration of said solution into said tissue is facilitated. In this embodiment, preferably said solution includes an ionic or nonionic chemical in an amount of from about 0.1 % to about 14 % of said solution, whereby the osmotic pressure effects of said solution is altered, thereby stabilizing said tissue for subsequent examination. A further embodiment, the preferably said solution contains an acid and/or an acid-salt and/or a chelating agent to effect decalcification of calcified portions of tissues.
In one embodiment of this first aspect of the invention there is provided a small sample of tissue from either a biopsy or a fresh cadaver that is treated with the solution (I) in an amount sufficient to prevent autolysis of the tissue by native enzymes that upon cessation of living state of the tissue operate to digest and to disintegrate the tissue, and to prevent other degenerative changes in the tissue.
In a further embodiment of this first aspect of the invention, there is provided a test-stable stool sample kit comprising means for maintaining a stool sample in a condition for evaluation at a later time by an appropriate laboratory including a female receptacle means and a male closure means and the stabilizing solution (I) . As a typical female receptacle means may be mentioned wide mouth jar containers of plastic or glass or the like with a screw pattern to accommodates a male screw cap closure. Another female receptacle means could be a bag or pouch, and the "male" closure could be a tie or clamp. It is to be understood that the female receptacle means may be of any shape, size or form provided it is such as to accommodate a sample of tissue, organ or bodily product that is to be inserted into the female receptacle means.
While various fixatives are known in the art, the stabilizing solution (I) reacts quickly with a variety of groups in the cell to stop enzyme actions, to fix structural features, to stop microbial actions and generally to maintain the sample in a manner as close to the form and appearance of the living tissue as possible, whereby the pathology examination is facilitated. While formaldehyde and other usually-used fixatives, when used alone, will provide acceptable microscopic appearing preparations, glyoxal used alone will not. The additional combination of components is required to provide good microscopic appearances.
In a second aspect of the invention, the stabilizing solution (I) is used to prepare parts or whole animals or plants in an anatomically preserved state for a prolonged period of time, and compositions useful in that method. The stabilizing solution (I) of the invention may be used to preserve frogs or other small animals for school laboratory dissection, or entire cadavers or individual organs for medical school instructional and other uses. The stabilizing solution (I) also facilitates the preservation of the specimen by killing and/or inhibiting any microorganisms that otherwise might be present or develop and thereby degrade the specimen.
Whereas in the first aspect of the invention, stabilization of a tissue sample was desired for a period of days, in this second aspect of the invention, stabilization for a prolonged period preferably measured in years, is the object. It is intended to be used with specimens such as frogs, fetal pigs, cadavers, cats, worms, insects or large organs that are to be used for study or dissection whether in a high school, college medical school, or autopsy setting, or other preservation uses.
It should be noted that the tissue may be of animal or plant origin. While human tissue, organs, or the entire organism are contemplated, it should be noted that the invention is contemplated
as applicable to any mammal, amphibian, reptile, bird, bony fish, cartilaginous fish, insect, arthropod, cephlapod, insect, multicellular microorganism, round worm, flat worm, segmented worm or any other animal or plant group. Depending on the specific application, it may be desirable to include at least one additional chemical such as mercuric salts, trichloroacetic acid, acetic acid, picric acid, potassium dichromate, phenol, biphenol, phenols, cresols, quaternary ammonium compounds, surfactants, antibiotics copper salts, sulfosalicylic acid, osmic acid, platinum salts, cadmium salts, cobalt salts and uranyl salts. Generally, the amount of any of these additional chemicals would be from about 0.07 % to about 16.5 %.
The following examples illustrate the invention:
EXAMPLE 1
To a glass container, there is added 100 ml of a 40 % solution of glyoxal and 900 ml of deionized water. With mixing, 5.0 g of sodium acid phosphate monohydrate and 6.5 g of anhydrous disodium phosphate are added and dissolved, the pH is slightly acid. Small pieces of dog tissue are immersed in the solution for several hours, and then are processed for histological examination. Good cellular detail is observed, with no evidence of autolysis or other degradative changes.
EXAMPLE 2
To a glass container, there is added, in order with mixing, 700 ml of deionized water, 200 ml of denatured ethyl alcohol and 150 ml of a 40 % glyoxal solution. Kidneys are cut in half so.that one- end serves as a control for the other end. Kidney halves are immersed in at least 10 times their volume of the said prepared solution and allowed to stand for varying periods of time. They then are prepared for pathological and histological examination. After 6 hours of exposure to the solution, the center-most portions of the kidney show good penetration of the solution whilst the controls that were immersed in the same solution without ethyl alcohol show very much poorer penetration in the center-most portions.
EXAMPLE 3
Kidneys prepared and treated in accordance with Example 2 are examined after 7 and 21 days of immersion in said solution. The kidneys remain in good stabilized condition suitable for pathologic and histologic examination. Good cellular detail is observed, without observable degradative changes.
EXAMPLE 4
To a glass container, there is added, in order with mixing, 700 ml of deionized water, 200 ml of ethylene glycol and 100 ml of a 40 % glyoxal solution. The solution is adjusted to pH 6.5 by the drop- wise addition of sodium hydroxide solution under conditions of continuous mixing. The solution is stored for a few days and then is used to stabilize pieces of human tissue prior to histologic processing and examination. Tissues processed with said solution show good preservation and cellular detail. Control tissues treated with the same solution absent the ethylene glycol show poorer preservation. Independent chemical analysis shows that the ethylene-glycol-containing solution has a higher glyoxal concentration than the solution absent the ethylene glycol.
EXAMPLE 5
To a glass container, there is added, in order with mixing, 500 ml of deionized water, 200 ml of denatured ethyl alcohol, 150 ml of glycerol, 60 ml of a 40 % glyoxal solution, and 50 ml of a 40 % solution of glyoxal. Intact rat livers are separated into individual lobes and the lobes are used as controls for different experimental conditions. In this example, lobes were immersed for 14 days in 10-fold excesses of said solution. The lobes are then processed and examined. Lobes treated with said solution show good preservation and good tissue consistency with no - evidence of "crumbliness." Control lobes immersed in the same solution absent the glycerol did not show the same tissue "pliability" and "softness." Microscopic examination of the test lobes treated with the solution in this example showed good cellular and microcellular detail. Control lobes treated with same solution except that the combination of dialdehydes was not used also show good cellular detail, but the uptake of stain was not as uniform in some sub- cellular details as was seen when the combination of dialdehydes was used.
EXAMPLE 6
To a glass container, there is added, in order with mixing, 850 ml of denatured ethyl alcohol, 50 ml of glacial acetic acid and 100 ml of a 40 % glyoxal solution. Various arachnids, insects and plant parts were immersed in said solution and were examined after one week, three weeks and nine months of immersion. All tissues, cells and organisms showed good preservation and good cellular detail.
EXAMPLE 7
To a glass container, there .is added, in order with mixing, 800 ml of deionized water, 45 g mercuric chloride, 5 g of sodium chloride, 20 g of trichloroacetic acid, 40 ml of glacial acetic acid, and 200 ml of 40 % glyoxal solution. Pieces of mammalian tissue are immersed in the solution for 3 to 24 hours. Slices less than 2 mm in thickness need only 3 hours of treatment. Subsequent processing and examination showed good preservation and good cellular detail with negligible shrinkage of connective tissue.
EXAMPLE 8 To a glass container, there is added, in order with mixing, 850 ml of deionized water, 10 g of formic acid, 100 g of trisodium citrate, and 100 ml of a 40 % glyoxal solution. Pieces of mammalian bone are immersed in at least a 10-fold excess of said solution and left for 5-7 days. Subsequent processing and examination show good preservation and good cellular detail. Calcified areas are completely decalcified and shrinkage is not observed.
EXAMPLE 9
The formic acid and sodium citrate in Example 8 were replaced with 100 g of disodium ethylene-diamine tetraacetate. Mammalian teeth were immersed in said modified solution and left for 7-10 days. Subsequent processing and examination showed good preservation and good structure Decalcification appears to complete.
EXAMPLE 10
A test-stable stool sample kit is provided which includes means for maintaining a stool sample in a condition suitable for analysis at a later time by an appropriate laboratory include a female receptacle means and a male closure means and 30 ml. of an aqueous solution which contains 40 % glyoxal. As a typical female receptacle means may be mentioned a 2 oz. wide mouth plastic container with a screw pattern to accommodates a male screw cap closure. It is to be understood that the female receptacle means may be of any shape, size or form provided it is such to accommodate a small scraping of bowel sample that is to be inserted into the female receptacle means.
Parasites which may be in the stool sample and which may be an object of laboratory examination are preserved in the stool samples to permit the stool sample to be properly used to identify the presence of such parasites.
EXAMPLE 11 In the test-stable stool sample kit of Example 10, the mentioned aqueous solution is replaced by 800 mg of dioxanediol (solid) , which is dissolved in 20 ml of an aqueous solution prior to inserting the stool sample. Parasites which may be in the stool sample and which may be an object of laboratory examination are preserved in the stool samples to permit the stool sample to be properly used to identify the presence of such parasites.
EXAMPLE 12
A freshly excised primate heart is perfused with a solution of glyoxal as prepared in Example 4 except that the pH was not adjusted. Following perfusion, the heart was left immersed in a closed container for 10 months, and then examined macroscopically and microscopically. The heart is preserved in good condition with no apparent degradative changes, and is suitable for student observation.
EXAMPLE 13
An adult bull frog is extinguished under ether, and is perfused with the solution described in Example 12 to which sodium chloride (0.6 %) and cetyltrimethylammonium bromide (0.15 %) have been added. The frog is kept moistened with same solution (under wetted cotton) in a closed container. The frog remains suitable for student dissection for a period of at least one year.

Claims

WHAT I CLAIM IS :
1. A method of providing pathology-stable tissue which comprises treating said tissue with an aqueous solution of a glyoxal in an amount sufficient to prevent major degenerative changes in said tissue, whereby said tissue remains in a state suitable for examination for micro- or macroscopic examination sufficient for a pathological or experimental examination.
2. A method of claim 1 wherein said glyoxal is in the form of an addition product.
3. A method of claim 1 wherein said tissue is of animal origin.
4. A method of claim 1 wherein said tissue is of mammalian origin.
5. A method of claim 1 wherein said tissue is of plant origin.
6. A method of claim 2 wherein said glyoxal is a glyoxal addition product comprised of glyoxal and a bisulfite, water, alcohol, or glycol addition product.
7. A method of claim 1, wherein said glyoxal is present in an amount of from about 0.08 % to about 36 % percent of the overall solution.
8. A method of claim 1, wherein said glyoxal is present in an amount of from about 0.2 % to about 20 % percent of the overall solution.
9. A method of claim 1, wherein said solution contains from about 0.15 % to about 36 % of a C1-4 alkane mono-, di-, or triol, whereby said solution is stabilized.
10. A method of claim 1 wherein said solution includes at least one C1_4 mono-, di-, or triol alkane at a concentration of from about 0.4 % to about 32 % of said solution, whereby the penetration of said solution into said tissue is facilitated.
11. A method of claim 1 wherein said solution includes an ionic or nonionic chemical in an amount of from about 0.1 % to about 14 % of said solution, whereby the osmotic pressure effects of said solution is altered, thereby stabilizing said tissue for subsequent examination.
12. A method of claim 1 wherein said solution includes from about 0.01 moles/liter to about 4.2 moles/liter of a pH buffering agent.
13. A method of claim 1 for simultaneously providing a pathology- stable tissue while decalcifying calcified regions within said tissue, wherein said solution contains an acid such as formic, hydrochloric, citric and/or nitric acids, and/or their alkali- metal or ammonium salts in amount of from about 0.3 % to about 75 %.
14. A method of claim 1 for simultaneously providing a pathology- stable tissue decalcifying calcified regions within said tissue, wherein said solution includes a chelating agent in an amount from about 0.1 % to about 18 %.
15. A method of claim 14 wherein said chelating agent is ethylene- dia ine-tetra-acetic acid, or an alkali-metal salt or ammonium salt thereof.
16. A kit for maintaining a pathology-stable preparation which comprises a female receptacle means and a male closure means and contained within said female receptacle means an aqueous solution of a glyoxal of claim 1 in an amount sufficient to prevent major degenerative changes in the sample reserved for pathological or experimental examination.
17. A kit for maintaining a stool sample in a form suitable for subsequent examination and recognition of parasites, worms and protozoans, which comprises a female receptacle means and a male closure means and the stabilizing solution of claim 1.
18. A method of claim 1 wherein said tissue is in the form of an organ or an entire organism which is to be preserved for a prolonged period of time, whereby said solution blocks the substantial degenerative changes within this period.
19. A composition capable of providing pathology-stable tissue when a tissue is immersed in said composition, said composition being an aqueous solution of a glyoxal addition product in an amount sufficient to prevent, major degenerative changes in said tissue, said glyoxal product being present in an amount of from about 0.08 % to about 35 % percent of the overall solution, and said solution including from about 0.15 % to about 36 % of a C2_4 mono, di-, or triol alkane as a stabilizing agent.
20. A composition of claim 19 wherein said solution includes at least one C2_4 mono, di- or triol alkane at a concentration of from about 0.4 % to about 32 % of said solution, whereby the penetration of said solution into said tissue is facilitated.
21. A composition of claim 19 wherein said solution includes an ionic or nonionic chemical in an amount of from about 0.1 % to about 14 % of said solution, whereby the osmotic pressure effects of said solution is altered, thereby stabilizing said tissue for subsequent examination.
22. A composition of claim 19 wherein said solution includes from about 0.01 moles/liter to about 4.2 moles/liter of a pH buffering agent.
23. A composition of claim 19 for simultaneously providing a pathology-stable tissue while decalcifying calcified regions within said tissue, wherein said solution contains an acid or an acid- salt which is formic, hydrochloric, citric or nitric acid in amount of from about 0.3 % to about 75 %.
24. A composition of claim 19 for simultaneously providing a pathology-stable tissuewhile decalcifying calcified regions within said tissue, wherein said solution includes a chelating agent in an amount from about 0.1 % to about 18 %.
25. A composition of claim 24 wherein said chelating agent is ethylene-diamine-tetra-acetic acid, or an alkali-metal salt or ammonium salt thereof.
PCT/US1992/007925 1991-09-20 1992-09-18 Methods and compositions with aldehyde stabilizing solution WO1993005650A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002119554A CA2119554C (en) 1991-09-20 1992-09-18 Method and compositions with aldehyde stabilizing solution
JP5506263A JPH07507266A (en) 1991-09-20 1992-09-18 Methods and compositions using aldehyde stabilizing solutions
EP92920955A EP0627879A1 (en) 1991-09-20 1992-09-18 Methods and compositions with aldehyde stabilizing solution
AU26835/92A AU669673B2 (en) 1991-09-20 1992-09-18 Methods and compositions with aldehyde stabilizing solution

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76230791A 1991-09-20 1991-09-20
US07/762,307 1991-09-20

Publications (1)

Publication Number Publication Date
WO1993005650A1 true WO1993005650A1 (en) 1993-04-01

Family

ID=25064679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/007925 WO1993005650A1 (en) 1991-09-20 1992-09-18 Methods and compositions with aldehyde stabilizing solution

Country Status (6)

Country Link
US (1) US5439667A (en)
EP (1) EP0627879A1 (en)
JP (1) JPH07507266A (en)
AU (1) AU669673B2 (en)
CA (1) CA2119554C (en)
WO (1) WO1993005650A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4223191A1 (en) * 1991-07-29 1994-01-20 Yeh Tso Li Solution for animal and plant preparations
EP1425383A2 (en) * 2001-08-23 2004-06-09 Immunivest Corporation Stabilization of cells and biological specimens for analysis
WO2010096323A1 (en) 2009-02-18 2010-08-26 Streck, Inc. Preservation of cell-free nucleic acids
US8796028B2 (en) 2005-12-30 2014-08-05 Qiagen Gmbh Method for treating a biological sample with a composition containing at least one polyol and excluding water
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
CN108601340A (en) * 2016-02-18 2018-09-28 阿达克斯生物科学有限公司 Anacidity glyoxal as the fixative for histological preparations
US10091984B2 (en) 2013-07-24 2018-10-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US10966421B2 (en) 2002-10-16 2021-04-06 Streck, Inc. Method and device for collecting and preserving cells for analysis
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US11299764B2 (en) 2015-11-20 2022-04-12 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US11506655B2 (en) 2016-07-29 2022-11-22 Streck, Inc. Suspension composition for hematology analysis control
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000651A1 (en) * 1995-06-20 1997-01-09 Agathos Efstathios A Human valve replacement with marine mammal valve
US7128903B2 (en) * 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
US20050255540A1 (en) * 2004-05-14 2005-11-17 Fredenburgh Jerry L Buffer system for formalin fixatives
US7531357B2 (en) * 2005-04-04 2009-05-12 Bio-Rad Laboratories, Inc. Preparation of platelet analogs
FR2910784B1 (en) * 2006-12-27 2009-02-20 Arkema France USE OF COMPOUNDS FOR PRESERVATION OF THE HUMAN OR ANIMAL BODY AND COMPOSITIONS COMPRISING SAME
US9714943B2 (en) 2010-12-30 2017-07-25 University Of South Florida Methods and materials for capture antibody targeted fluorescent in-situ hybridization (CAT-FISH)
US10107727B2 (en) * 2015-12-30 2018-10-23 Sakura Finetek U.S.A., Inc. Tissue processing reagent
JP2021075506A (en) * 2019-11-13 2021-05-20 学校法人北里研究所 Discoloration-resistant sample fixing agent and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2333182A (en) * 1942-10-24 1943-11-02 Hizone Products Embalming composition
US4136161A (en) * 1976-03-16 1979-01-23 Ortho Diagnostics, Inc. Stabilized erythrocytes and methods therefor
US4857300A (en) * 1987-07-27 1989-08-15 Cytocorp, Inc. Cytological and histological fixative formulation and methods for using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2048152A5 (en) * 1969-06-03 1971-03-19 Anvar
US4493821A (en) * 1982-02-04 1985-01-15 Harrison James S Preservative and fixative preparations for biological systems
DE3319564A1 (en) * 1983-05-30 1984-12-06 Arthur Pfeiffer Vakuumtechnik Wetzlar Gmbh, 6334 Asslar METHOD FOR PRODUCING FLEXIBLE, SUSTAINABLY MADE NON-PRESERVED AND PRESERVED BIOLOGICAL MATERIALS
US4946669A (en) * 1987-10-09 1990-08-07 Siegfried Barry A Histological fixatives
US5001047A (en) * 1988-07-14 1991-03-19 Barnet L. Liberman Method of preserving organs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2333182A (en) * 1942-10-24 1943-11-02 Hizone Products Embalming composition
US4136161A (en) * 1976-03-16 1979-01-23 Ortho Diagnostics, Inc. Stabilized erythrocytes and methods therefor
US4857300A (en) * 1987-07-27 1989-08-15 Cytocorp, Inc. Cytological and histological fixative formulation and methods for using same

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4223191A1 (en) * 1991-07-29 1994-01-20 Yeh Tso Li Solution for animal and plant preparations
EP1425383A2 (en) * 2001-08-23 2004-06-09 Immunivest Corporation Stabilization of cells and biological specimens for analysis
EP1425383A4 (en) * 2001-08-23 2005-11-09 Immunivest Corp Stabilization of cells and biological specimens for analysis
AU2008288601B2 (en) * 2001-08-23 2012-05-31 Veridex, Llc Stabilization of cells and biological specimens for analysis
US11647743B2 (en) 2002-10-16 2023-05-16 Streck Llc Method and device for collecting and preserving cells for analysis
US10966421B2 (en) 2002-10-16 2021-04-06 Streck, Inc. Method and device for collecting and preserving cells for analysis
US8796028B2 (en) 2005-12-30 2014-08-05 Qiagen Gmbh Method for treating a biological sample with a composition containing at least one polyol and excluding water
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
US10294513B2 (en) 2009-02-18 2019-05-21 Streck, Inc. Preservation of cell-free nucleic acids
EP2398912B1 (en) * 2009-02-18 2017-09-13 Streck Inc. Preservation of cell-free nucleic acids
US10689686B2 (en) 2009-02-18 2020-06-23 Streck, Inc. Preservation of cell-free nucleic acids
EP2398912A1 (en) * 2009-02-18 2011-12-28 Streck Inc. Preservation of cell-free nucleic acids
WO2010096323A1 (en) 2009-02-18 2010-08-26 Streck, Inc. Preservation of cell-free nucleic acids
US9926590B2 (en) 2009-02-18 2018-03-27 Streck, Inc. Devices and compositions for preservation of cell-free nucleic acids
US10144955B2 (en) 2009-02-18 2018-12-04 Streck, Inc. Methods for preservation of cell-free nucleic acids
US9657227B2 (en) 2009-02-18 2017-05-23 Streck, Inc. Preservation of cell-free RNA in blood samples
US11761025B2 (en) 2009-02-18 2023-09-19 Streck Llc Preservation of cell-free nucleic acids
US20180216165A1 (en) 2009-02-18 2018-08-02 Streck, Inc. Preservation of cell-free nucleic acids
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US10091984B2 (en) 2013-07-24 2018-10-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US11547111B2 (en) 2013-07-24 2023-01-10 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US10674721B2 (en) 2013-07-24 2020-06-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US11299764B2 (en) 2015-11-20 2022-04-12 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
CN108601340A (en) * 2016-02-18 2018-09-28 阿达克斯生物科学有限公司 Anacidity glyoxal as the fixative for histological preparations
US11506655B2 (en) 2016-07-29 2022-11-22 Streck, Inc. Suspension composition for hematology analysis control

Also Published As

Publication number Publication date
CA2119554C (en) 2003-05-06
AU669673B2 (en) 1996-06-20
JPH07507266A (en) 1995-08-10
EP0627879A1 (en) 1994-12-14
US5439667A (en) 1995-08-08
AU2683592A (en) 1993-04-27
EP0627879A4 (en) 1994-09-20
CA2119554A1 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
US5998483A (en) Glyoxal-containing preservative compositions
US5439667A (en) Method for preserving tissue for microscopic examination using an osmotically controlled glyoxal solution
US5429797A (en) Safe dialdehydes useful as decontaminants, fixatives, preservatives and embalming agents
CA1323550C (en) Histological fixatives
Hayat Fixation for electron microscopy
JP3294299B2 (en) Cell storage solution
Marsh et al. Hypothermic preservation of hepatocytes: I. Role of cell swelling
Gordon et al. Osmotic regulation in the tadpoles of the crab-eating frog (Rana cancrivora)
CN101601377B (en) Long-term antiseptic preserving fluid of remains and application thereof
JP2768558B2 (en) Preservatives for dissection and biology, improved cadaver preservative compositions and preservative treatment methods
Lahnsteiner et al. Semen cryopreservation of salmonid fishes: influence of handling parameters on the postthaw fertilization rate
US5482676A (en) Visualization system for retrieval, identification, and positioning of biological samples for subsequent microscopic examination
US5622695A (en) Anatomical and biological preservative and method
US3573082A (en) Biological specimens and process of preserving same
JP3405733B2 (en) Compositions containing dialkyl peroxide (C ▲ 1〜 to C ▲ 66) ketones for preserving organic tissue and use of the compositions in preservation and anatomical preparation of organic tissues of animals or humans
Al-Maaini et al. The effectiveness of honey as a substitute for formalin in the histological fixation of tissue
Ruben et al. Serial section radioautography of the inner ear: histological technique
US11280707B1 (en) Tissue preservation
Rosenquist et al. Skin preservation at 4 C: A species comparison
Ajileye et al. Fixation and fixatives in histopathology: a review
Asakura The anal portion as a salt-excreting organ in a seawater mosquito larva, Aedes togoi Theobald
Schlisio et al. Osmotic and ionic regulation in Xenopus laevis Daud. During adaptation to different osmotic environments—V. Quantitative alterations of the acid glycosaminoglycans in the kidney
RU2752505C1 (en) Formaldehyde-free biomaterial fixator for histological and immunohistochemical studies
Doyle Cytological changes in chloride cells following altered ionic media
CN114839020A (en) Cell pathology slide fixing solution and preparation method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2119554

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992920955

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992920955

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1992920955

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992920955

Country of ref document: EP